Faron Pharmaceuticals Oy Director/PDMR Shareholding (0505D)
22 April 2017 - 2:56AM
UK Regulatory
TIDMFARN
RNS Number : 0505D
Faron Pharmaceuticals Oy
21 April 2017
Faron Pharmaceuticals Oy
("Faron" or the "Company")
Director's dealings
TURKU - FINLAND, 21 April 2017 - Faron Pharmaceuticals Ltd
("Faron") (LON: FARN), the clinical stage biopharmaceutical
company, announces that it has been notified that Dr Jonathan
Knowles, a Non-Executive Director of the Company, acquired 10,000
ordinary shares in Faron at a price of GBP2.65 per share on 12
December 2016, 7,000 ordinary shares in Faron at a price of GBP2.75
per share on 13 December 2016 and 19,000 ordinary shares in Faron
at a price of GBP5.50 per share on 31 March 2017. Following these
purchases, Dr Knowles holds 46,712 ordinary shares in the
Company.
The notification below, which has been made in accordance with
the requirements of the EU Market Abuse Regulation, provides
further detail.
For more information please contact:
Faron Pharmaceuticals Ltd
Dr Markku Jalkanen, Chief Executive Officer
investor.relations@faron.com
Consilium Strategic Communications
Mary-Jane Elliott, Chris Welsh, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com
Westwicke Partners, IR (US)
Chris Brinzey
Phone: 01 339 970 2843
E-Mail: chris.brinzey@westwicke.com
Cairn Financial Advisers LLP, Nominated Adviser
Emma Earl, Tony Rawlinson, Rebecca Anderson
Phone: +44 207 213 0880
Panmure Gordon (UK) Limited, Joint Broker
Freddy Crossley, Duncan Monteith (Corporate Finance)
Tom Salvesen (Corporate Broking)
Phone: +44 207 886 2500
Whitman Howard Limited, Nominated Broker (UK)
Ranald McGregor-Smith, Francis North
Phone: +44 207 659 1234
About Faron Pharmaceuticals Ltd
Faron is a clinical stage biopharmaceutical company developing
novel treatments for medical conditions with significant unmet
needs. The Company currently has a pipeline focusing on acute organ
traumas, cancer immunotherapy and vascular damage. The pipeline is
built on Faron's scientific knowledge and control of the
endothelial barrier, the membrane of cells lining blood and
lymphatic vessels to separate blood content from tissues. The
Company's lead candidate Traumakine(R) is in development for the
treatment of Acute Respiratory Distress Syndrome ("ARDS"), a rare,
severe, life-threatening medical condition characterised by
widespread inflammation in the lungs. Traumakine is currently in
pan-European (INTEREST) and Japanese pivotal Phase III studies.
Additionally, Faron is developing Clevegen(R) a ground breaking
pre-clinical anti-Clever-1 antibody. Clevegen has the ability to
convert the immune environment around a tumour from being immune
suppressive to immune stimulating. This novel macrophage-directed
immuno-oncology approach is called Tumour Immunity Enabling
Technology ("TIET") and can be used alone or in combination with
other immune checkpoint molecules for the treatment of cancer
patients. New application opportunities related to TIET cover
chronic infections and inefficient vaccination. Based in Turku,
Finland, Faron Pharmaceuticals is listed on AIM under the ticker
'FARN'. Further information is available at
www.faronpharmaceuticals.com
Notification of a Transaction pursuant to Article
19(1) of Regulation (EU) No. 596/2014
-----------------------------------------------------------------------
1 Details of the person discharging managerial
responsibilities/person closely associated
---- -----------------------------------------------------------------
a. Name Jonathan Knowles
----------------------------------------
2 Reason for
notification
---- ----------------------- ----------------------------------------
a. Position/Status Director
---- ----------------------- ----------------------------------------
b. Initial notification/ Initial Notification
Amendment
---- ----------------------- ----------------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
-----------------------------------------------------------------
a. Name Faron Pharmaceuticals Oy
---- ----------------------- ----------------------------------------
b. LEI 7437009H31TO1DC0EB42
---- ----------------------- ----------------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
---- -----------------------------------------------------------------
a. Description Ordinary shares
of the financial
instrument, ISIN: FI4000153309
type of instrument
Identification
Code
---- ----------------------- ----------------------------------------
b. Nature of the Purchase of Ordinary Shares
transaction
---- ----------------------- ----------------------------------------
c. Price(s) and Price(s) Volume(s)
volume(s)
---- ----------------------- -------------------- ----------
GBP2.65 7,000
GBP2.75 10,000
GBP5.50 19,000
-------------------- ----------
Aggregated
information
- Aggregated
Volume
d. - Price 36,000
---- ----------------------- ----------------------------------------
e. Date of the 12 December 2016, 13 December
transaction 2016 and 31 March 2017
---- ----------------------- ----------------------------------------
f. Place of the London
transaction
---- ----------------------- ----------------------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHOKDDPABKDPQB
(END) Dow Jones Newswires
April 21, 2017 12:56 ET (16:56 GMT)
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From Apr 2024 to May 2024
Faron Pharmaceuticals Oy (LSE:FARN)
Historical Stock Chart
From May 2023 to May 2024